09.05.2012 • NewsNovozymesbiopharmaceuticalscGMP

Novozymes Now Supplying Pharmaceutical Grade Q7 cGMP Hyaluronic Acid

Novozymes Biopharma, part of Novozymes, has announced the first shipment of the company's Bacillus-derived hyaluronic acid, Hyasis, from its newly inaugurated manufacturing facility in China, which represents an investment of more than DKK 350 million.

The facility in Tianjin employs a patented water-based process to manufacture Hyasis to Q7 cGMP standards.

The first commercial products using Hyasis as a raw material are expected to reach the market in Q2 of this year.

 

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read